Update on Molecular Imaging in Parkinson's Disease.
10.1007/s12264-017-0202-6
- Author:
Zhen-Yang LIU
1
;
Feng-Tao LIU
1
;
Chuan-Tao ZUO
2
;
James B KOPRICH
1
;
Jian WANG
3
Author Information
1. Department of Neurology and National Clinical Research Center for Ageing and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.
2. PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China.
3. Department of Neurology and National Clinical Research Center for Ageing and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China. wangjian336@hotmail.com.
- Publication Type:Journal Article
- Keywords:
Parkinson’s disease;
Positron emission tomography;
SPECT
- MeSH:
Brain;
diagnostic imaging;
Humans;
Molecular Imaging;
methods;
trends;
Neuroimaging;
methods;
trends;
Parkinson Disease;
diagnostic imaging
- From:
Neuroscience Bulletin
2018;34(2):330-340
- CountryChina
- Language:English
-
Abstract:
Advances in radionuclide tracers have allowed for more accurate imaging that reflects the actions of numerous neurotransmitters, energy metabolism utilization, inflammation, and pathological protein accumulation. All of these achievements in molecular brain imaging have broadened our understanding of brain function in Parkinson's disease (PD). The implementation of molecular imaging has supported more accurate PD diagnosis as well as assessment of therapeutic outcome and disease progression. Moreover, molecular imaging is well suited for the detection of preclinical or prodromal PD cases. Despite these advances, future frontiers of research in this area will focus on using multi-modalities combining positron emission tomography and magnetic resonance imaging along with causal modeling with complex algorithms.
